

Publications for Phoebe Joy Ho

2018

Hsu, J., Bryant, C., Papadimitriou, M., Kong, B., Gasiorowski, R., Orellana, D., McGuire, H., Fazekas de St Groth, B., Joshua, D., Ho, P., Iland, H., Gibson, J., Clark, G., Fromm, P., Hart, D., et al (2018). A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission. *OncoImmunology*, 7(4), e1419114-1-e1419114-11. [More Information]

Thompson, A., Walters, M., Kwiatkowski, J., Rasko, J., Ribeil, J., Hongeng, S., Magrin, E., Schiller, G., Payen, E., Semeraro, M., Ho, P., et al (2018). Gene Therapy in Patients with Transfusion-Dependent [Beta]-Thalassemia. *New England Journal of Medicine*, 378(16), 1479-1493. [More Information]

Scott, A., Weber, N., Tiley, C., Taylor, K., Taper, J., Harrison, S., Chan, K., Stark, R., Lee, C., Morris, K., Ho, P., et al (2018). Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma. *Leukemia & Lymphoma*, 59(6), 1514-1516. [More Information]

2017

Ho, P., Bajel, A., Burbury, K., Dunlop, L., Durrant, S., Forsyth, C., Perkins, A., Ross, D. (2017). A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis. *Internal Medicine Journal*, 47(3), 262-268. [More Information]

Ho, P., Tay, L., Teo, J., Marlton, P., Grigg, A., St Pierre, T., Brown, G., Badcock, C., Traficante, R., Gervasio, O., et al (2017). Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study). *European Journal of Haematology*, 98(2), 97-105. [More Information]

Quach, H., White, D., Spencer, A., Ho, P., Bhutani, D., White, M., Inamdar, S., Morris, C., Ou, Y., Gyger, M. (2017). Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal disease (ESRD): an open-label, single-arm, phase I study. *Cancer Chemotherapy and Pharmacology*, 79(6), 1067-1076. [More Information]

Ho, P., Jelfs, P., Nguyen, P., Sintchenko, V., Fox, G., Marks, G. (2017). Pooling sputum samples to improve the feasibility of Xpert(i₂/2) MTB/RIF in systematic screening for tuberculosis. *International Journal of Tuberculosis and Lung Disease*, 21(5), 503-508. [More Information]

Talaulikar, D., Tam, C., Joshua, D., Ho, P., Szer, J., Quach, H., Spencer, A., Harrison, S., Mollee, P., Roberts, A., Gibson, J., Trotman, J., Ward, C., et al (2017). Treatment of patients with Waldenstrom macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. *Internal Medicine Journal*, 47(1), 35-49. [More

Information]

2016

Bryant, C., Fromm, P., Kupresanin, F., Clark, G., Lee, K., Clarke, C., Silveira, P., Suen, H., Brown, R., Newman, E., Ho, P., Bradstock, K., Joshua, D., Hart, D., et al (2016). A CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subset. *Immunology and Cell Biology*, 94(5), 447-457. [More Information]

Bergin, K., Moore, E., McQuilten, Z., Wood, E., Augustson, B., Blacklock, H., Ho, P., Horvath, N., King, T., McNeil, J., et al (2016). Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry. *BMC Medical Research Methodology*, 16(1), 1-8. [More Information]

Crighton, G., Wood, E., Scarborough, R., Ho, P., Bowden, D. (2016). Haemoglobin disorders in Australia: where are we now and where will we be in the future? *Internal Medicine Journal*, 46(7), 770-779. [More Information]

Suen, H., Brown, R., Yang, S., Weatherburn, C., Ho, P., Woodland, N., Nassif, N., Barbaro, P., Bryant, C., Hart, D., Gibson, J., Joshua, D. (2016). Multiple myeloma causes clonal T-cell immunosenescence: Identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. *Leukemia*, 30(8), 1716-1724. [More Information]

Joshua, D., Suen, H., Brown, R., Bryant, C., Ho, P., Hart, D., Gibson, J. (2016). The T cell in myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, 16(10), 537-542. [More Information]

2015

Weber, N., Mollee, P., Augustson, B., Brown, R., Catley, L., Gibson, J., Harrison, S., Ho, P., Horvath, N., Jaksic, W., et al (2015). Management of Systemic AL Amyloidosis: Recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. *Internal Medicine Journal*, 45(4), 371-382. [More Information]

Brown, R., Yang, S., Weatherburn, C., Gibson, J., Ho, P., Suen, H., Hart, D., Joshua, D. (2015). Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma. *Leukemia*, 29(2), 483-490. [More Information]

Ho, P., Marlton, P., Tam, C., Stevenson, W., Ritchie, D., Bird, R., Dunlop, L., Durrant, S., Ross, D. (2015). Practical management of myelofibrosis with ruxolitinib. *Internal Medicine Journal*, 45(12), 1221-1230. [More Information]

Suen, H., Brown, R., Yang, S., Ho, P., Gibson, J., Joshua, D. (2015). The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study. *Leukemia*, 29(7), 1621-1622. [More Information]

Ho, P., Marks, G., Fox, G. (2015). The impact of sputum quality on tuberculosis diagnosis: a systematic review. *International Journal of Tuberculosis and Lung Disease*, 19(5), 537-544. [More Information]

Quach, H., Joshua, D., Ho, P., Szer, J., Spencer, A., Harrison, S., Mollee, P., Roberts, A., Horvath, N., Talulikar, D., Gibson, J., et al (2015). Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: Position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. *Internal Medicine Journal*, 45(1), 94-105. [More Information]

Quach, H., Joshua, D., Ho, P., Szer, J., Spencer, A., Harrison, S., Mollee, P., Roberts, A., Horvath, N., Talaulikar, D., Gibson, J., et al (2015). Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group. *Internal Medicine Journal*, 45(3), 335-343. [More Information]

Brown, R., McAuliffe, S., Catalano, A., Ho, P., Nassif, N., Woodland, N., Hart, D., Weatherburn, C., Yang, S., Suen, H., Joshua, D., et al (2015). Using digital polymerase chain reaction to detect minimal residual disease in myeloma by identifying FGFR3 up-regulation. *Leukemia & Lymphoma*, 56(9), 2714-2716. [More Information]

2014

Favaloro, J., Brown, R., Aklilu, E., Yang, S., Suen, H., Hart, D., Fromm, P., Gibson, J., Khoo, L., Ho, P., Joshua, D. (2014). Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. *Leukemia & Lymphoma*, 55(5), 1090-1098. [More Information]

2013

Bryant, C., Suen, H., Brown, R., Yang, S., Favaloro, J., Aklilu, E., Gibson, J., Ho, P., Iland, H., Fromm, P., Hart, D., Joshua, D., et al (2013). Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance. *Blood Cancer Journal*, 3, 1-7. [More Information]

2012

Ling, S., Lau, K., Al-Shabeeb, A., Nikolic, A., Catalano, A., Iland, H., Horvath, N., Ho, P., Harrison, S., Fleming, S., Joshua, D., Allen, J. (2012). Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. *Haematologica*, 97(1), 64-72. [More Information]

Ho, P., Brown, R., Spencer, A., Jeffels, M., Daniher, D., Gibson, J., Joshua, D. (2012). Thalidomide consolidation

improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial. *Leukemia & Lymphoma*, 53(9), 1728-1734. [More Information]

2011

Ho, P., Tay, L., Lindeman, R., Catley, L., Bowden, D. (2011). Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias. *Internal Medicine Journal*, 41(7), 516-524. [More Information]

Viprakasit, V., Ibrahim, H., Ha, S., Ho, P., Li, C., Chan, L., Chiu, C., Sutcharitchan, P., Habr, D., Domokos, G., et al (2011). Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox. *International Journal of Hematology (online)*, 93(3), 319-328. [More Information]

2007

Loh, Y., Mo, S., Brown, R., Yamagishi, T., Yang, S., Joshua, D., Ho, P., Gibson, J., Roufogalis, B., Sze, D. (2007). Characteristics of 'side population' as the putative cancer stem cells in myeloma: Cell growth and differentiation capability. *Molecular Cancer Therapeutics*, 6(12), 3365s-3366s.

Sanders, J., Crawford, B., Gibson, J., Ho, P., Iland, H., Joshua, D. (2007). Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS). *International Journal of Laboratory Hematology*, 29(5), 395-397. [More Information]

Ling, S., Campbell, L., Ho, P., Gibson, J., Joshua, D. (2007). Molecular Biology, Pathology, and Cytogenetics. In Mikkael A. Sekeres, Matt E. Kalaycio, Brian J. Bolwell (Eds.), *Clinical Malignant Haematology*, (pp. 847-857). United States: McGraw Hill.

Osborn, R., de Abreu Lourenço, R., Dalton, A., Houltram, J., Downton, D., Joshua, D., Lindeman, R., Ho, P. (2007). Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. *Value in Health*, 10(6), 451-456. [More Information]

2006

Trent, R., Webster, B., Bowden, D., Gilbert, A., Ho, P., Lindeman, R., Lammi, A., Rowell, J., Hinchcliffe, M., Colley, A., et al (2006). Complex phenotypes in the haemoglobinopathies: recommendations on screening and DNA testing. *Pathology*, 38(6), 507-519. [More Information]

Sze, D., Brown, R., Yang, S., Ho, P., Gibson, J., Joshua, D. (2006). The use of thalidomide in myeloma therapy as an effective anticancer drug. *Current Cancer Drug Targets*, 6(4), 325-331. [More Information]

Ling, S., Joshua, D., Gibson, J., Young, G., Iland, H., Watson, G., Ho, P. (2006). Transformation and Progression of Waldenström's Macroglobulinemia Following Cladribine

Therapy in Two Cases: Natural Evolution or Iatrogenic Causation? *American Journal Of Hematology*, 81(2), 110-114. [More Information]

2005

Brown, R., Ho, P. (2005). Identification of Malignant Plasma Cells by mRNA In Situ Hybridization. *Methods in molecular medicine*, 113, 175-181.

Joshua, D., Brown, R., Ho, P. (2005). Multiple myeloma: challenges and opportunities. *Methods in molecular medicine*, 113(Multiple Myeloma: Methods and Protocols), 1-4.

Ho, P. (2005). *Multiple Myeloma: Methods and Protocols*. Totowa, NJ, USA: Humana Press.

Gibson, J., Joshua, D., Ho, P., Campbell, L., Ling, S. (2005). Multiple Myeloma: molecular biology, Pathology and Cytogenetics. In Susan Hallam, Ian Cross, Michael Thaut (Eds.), *Oxford Handbook of Music Psychology*. Oxford, UK: Oxford University Press.

2004

Brown, R., Murray, A., Pope, B., Sze, D., Gibson, J., Ho, P., Joshua, D. (2004). B7+ T Cells In Myeloma: An Acquired Marker Of Prior Chronic Antigen Presentation. *Leukemia and Lymphoma*, 45(2), 363-371. [More Information]

Brown, R., Murray, A., Pope, B., Sze, D., Gibson, J., Ho, P., Hart, D., Joshua, D. (2004). Either Interleukin-12 Or Interferon- β Can Correct The Dendritic Cell Defect Induced By Transforming Growth Factor β_1 ? In Patients With Myeloma. *British Journal of Haematology*, 125(2), 743-748. [More Information]

Gibson, J., Ho, P., Joshua, D. (2004). Evolving Transplant Options For Multiple Myeloma: Autologous And Nonmyeloablative Allogenic. *Transplantation Proceedings*, 36(8), 2501-2503. [More Information]

Gibson, J., Ho, P., Joshua, D. (2004). Low-Grade Lymphoma: The Optimal Timing. *Transplantation Proceedings*, 36(7), 1995-1998. [More Information]

Joshua, D., Gibson, J., Brown, R., Ho, P. (2004). The Immune System In Myeloma. In Gosta Garton, Brian Durie, Diana Samson (Eds.), *Multiple myeloma and related disorders*, (pp. 29-46). UK: Hodder Arnold.

Ho, P., Gibson, J., Joshua, D. (2004). Treatment Of Multiple Myeloma: Current Management And New Approaches. *American Journal of Cancer*, 3(1), 47-66. [More Information]

2003

Sze, D., Brown, R., Yuen, E., Gibson, J., Ho, P., Raitakari, M., Basten, A., Joshua, D., Fazekas de St Groth, B. (2003). Clonal Cytotoxic T Cells in Myeloma. *Leukemia and Lymphoma*, 44(10), 1667-1674. [More Information]

Sze, D., Brown, R., Yang, S., Gibson, J., Ho, P., Fazekas de St Groth, B., Basten, A., Joshua, D. (2003). Prediction of high

affinity class I-restricted multiple myeloma idiotype peptide epitopes. *Leukemia and Lymphoma*, 44(9), 1557-1568. [More Information]

2002

Ho, P. (2002). Chromosomal and genetic abnormalities in myeloma. *Clinical and Laboratory Haematology*, , 259-269. [More Information]

Ho, P., Gibson, J., Joshua, D., Campbell, L., Brown, R. (2002). The biology and cytogenetics of multiple myeloma. *Reviews in Clinical and Experimental Hematology*, 6(3), 276-300. [More Information]

2001

Sze, D., Giesajtis, G., Brown, R., Raitakari, M., Gibson, J., Ho, P., Baxter, A., Fazekas de St Groth, B., Basten, A., Joshua, D. (2001). Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+CD57+CD28- compartment. *Blood*, 98(9), 2817-2827.

Ho, P., Basten, A., Gibson, J., Joshua, D., Brown, R., Pelka, G. (2001). Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival. *Blood*, 97, 490-495.

2000

Ho, P., Thein, S. (2000). Gene regulation and deregulation: a beta globin perspective. *Blood Reviews*, 14, 78-93.